title: A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.
abstract: Chronically hypoxic rats (exposed to 5000 m elevation for 3 weeks) develop pulmonary hypertension (PH) that is reversed upon return to normoxia and is blocked by bradykinin (BK) antagonist B9430 treatment (100 microg/kg s.c. three times per week). Treatment of rats with both the synthetic VEGF receptor-1/2 antagonist 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one (SU5416) (200 mg/kg, single s.c. injection) and hypoxia (3 weeks) causes irreversible severe PH characterized by marked elevation of pulmonary artery pressure (PAP), right ventricular hypertrophy, and obliteration of pulmonary arteries by proliferating endothelial cells (EC). Between weeks I and 2 of treatment, there is increased apoptotic EC death and caspase-3 activity. The combination of hypoxia with VEGFR-1 and -2 blockade appears to cause death of normal lung EC and proliferation of an apoptosis-resistant proliferating EC phenotype. Cotreatment with BK antagonist B9430 and (or) the broad caspase inhibitor Z-Asp-2,6-dichlorobenzoyloxymethylketone (Z-Asp) (2 mg/kg three times per week) prevented development of severe PH and caused significant reduction of PAP: 39.7 +/- 4.6 mmHg in Z-Asp + SU5416, 37.1 +/- 1.2 mmHg in BK antagonist B9430 + SU5416, 27.2 +/- 0.7 mmHg in Z-Asp alone, and 36.6 +/- 3.0 mmHg in BK antagonist alone versus 48 +/- 1.7 mmHg in SU5416-treated rats and 32.8 +/-1.4 mmHg in vehicle-treated controls. The PAP correlated with the right ventricular mass. Pulmonary arteries of rats treated with Z-Asp and BK antagonist B9430 had a marked reduction of intravascular EC, yet there was still evidence of medial muscular hypertrophy, similar to that observed in chronically hypoxic rats not treated with SU5416. We conclude that EC death induced by VEGFR-2 blockade with SU5416 may trigger an EC selection process that allows for the expansion of apoptosis-resistant EC, possibly driven by mechanisms independent of VEGF and VEGFR-2.
authors.affiliation: Pulmonary Hypertension Center, University of Colorado School of Medicine, Denver 80262, USA. Laima.Taraseviciene@uchsc.edu
authors.forename: Laimute
authors.initials: L
authors.lastname: Taraseviciene-Stewart
authors.forename: Lajos
authors.initials: L
authors.lastname: Gera
authors.forename: Peter
authors.initials: P
authors.lastname: Hirth
authors.forename: Norbert F
authors.initials: NF
authors.lastname: Voelkel
authors.forename: Rubin M
authors.initials: RM
authors.lastname: Tuder
authors.forename: John M
authors.initials: JM
authors.lastname: Stewart
mesh_terms: D000818:Animals; D065168:Bradykinin Receptor Antagonists; D061945:Caspase Inhibitors; D020169:Caspases / Q000502:physiology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000201:enzymology / Q000517:prevention & control*; D000860:Hypoxia / Q000188:drug therapy / Q000201:enzymology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D018002:Receptors, Bradykinin / Q000502:physiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D065168:Bradykinin Receptor Antagonists; D061945:Caspase Inhibitors; D004791:Enzyme Inhibitors; D018002:Receptors, Bradykinin; D040262:Receptors, Vascular Endothelial Growth Factor; D020169:Caspases